GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OSTO:BIOT) » Definitions » Peter Lynch Fair Value

Biotage AB (OSTO:BIOT) Peter Lynch Fair Value : kr33.10 (As of Dec. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Biotage AB Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Biotage AB's PEG is 1. Biotage AB's 5-Year TTM EBITDA Growth Rate is 10.03. Biotage AB's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was kr3.30. Therefore, the Peter Lynch Fair Value for today is kr33.10.

As of today (2024-12-15), Biotage AB's share price is kr161.90. Biotage AB's Peter Lynch fair value is kr33.10. Therefore, Biotage AB's Price to Peter Lynch Fair Value Ratio for today is 4.89.


The historical rank and industry rank for Biotage AB's Peter Lynch Fair Value or its related term are showing as below:

OSTO:BIOT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.04   Med: 2.17   Max: 5.64
Current: 4.89


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Biotage AB was 5.64. The lowest was 1.04. And the median was 2.17.


OSTO:BIOT's Price-to-Peter-Lynch-Fair-Value is ranked worse than
83.98% of 181 companies
in the Medical Devices & Instruments industry
Industry Median: 1.78 vs OSTO:BIOT: 4.89

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Biotage AB Peter Lynch Fair Value Historical Data

The historical data trend for Biotage AB's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Peter Lynch Fair Value Chart

Biotage AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.80 64.48 75.91 77.85 42.31

Biotage AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.65 42.31 35.97 34.85 33.10

Competitive Comparison of Biotage AB's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, Biotage AB's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Biotage AB's Price-to-Peter-Lynch-Fair-Value falls into.



Biotage AB Peter Lynch Fair Value Calculation

Biotage AB's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 10.03 *3.3
=33.10

Biotage AB's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.30.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Biotage AB  (OSTO:BIOT) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.03 instead of 15 in this case.

Biotage AB's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=161.90/33.10
=4.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotage AB Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Biotage AB's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By GlobeNewswire GlobeNewswire 02-02-2023